LISATA THERAPEUTICS, INC.
LSTANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $170,000 | $1.0M | $0 | $0 | — | — |
| Operating income | −$18.2M | −$22.4M | −$25.7M | −$57.6M | −$29.1M | −$19.1M |
| Net income | −$16.6M | −$20.0M | −$20.8M | −$54.2M | −$27.5M | −$8.2M |
| Total assets | $17.7M | $35.0M | $54.7M | $73.0M | $97.0M | $36.0M |
| Total liabilities | $3.1M | $5.7M | $6.8M | $6.7M | $5.0M | $3.8M |
| Equity | $14.9M | $29.6M | $48.1M | $66.6M | $92.3M | $32.5M |
| EPS (diluted) | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-7.45 | $-0.53 |
| Shares out. | 8.6M | 8.3M | 8.0M | 60.5M | 59.5M | 10.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −10711.2%
- Net margin
- −9756.5%
- Return on equity
- −111.7%
- Return on assets
- −93.5%
- Return on capital (ROCE)
- −124.1%
- Liabilities / assets
- 17.7%
- Debt / equity
- 0.21×
- Book value / share
- $1.72
- Revenue growth (YoY)
- −83.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -100.26distress
- Accruals / assets
- −3.6%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 17, 2011
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2011
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Mazzo David JOfficer — President & CEO | Jan 9, 2026 | Grant | 81,000 | $0.00 |
| Nisco JamesOfficer — SVP, Fin/Treas, Chief Actg Off | Jan 9, 2026 | Grant | 15,000 | $0.00 |
| Imam TariqOfficer — SVP, Bus Dev, General Counsel | Jan 9, 2026 | Grant | 15,000 | $0.00 |
| Buck Kristen KOfficer — EVP, R&D and CMO | Jan 9, 2026 | Grant | 25,000 | $0.00 |
| Klosk Steven MDirector | Jan 9, 2026 | Grant | 30,456 | $0.00 |
| Henson HeidiDirector | Jan 9, 2026 | Grant | 30,456 | $0.00 |
| Flowers Cynthia LouiseDirector | Jan 9, 2026 | Grant | 30,456 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 93,493 | 3.0 | +33.1% |
| Apr 30, 2026 | 70,246 | 1.0 | +36.0% |
| Apr 15, 2026 | 51,644 | 1.0 | +204.9% |
| Mar 31, 2026 | 16,935 | 1.0 | +14.9% |
| Mar 13, 2026 | 14,741 | 1.0 | -3.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventJun 1, 2026
- Entered a material agreementMay 29, 2026
- Entered a material agreementMay 4, 2026
- Other material eventApr 15, 2026
- Other material eventApr 3, 2026
- Entered a material agreement · Regulation FD disclosureMar 9, 2026
- Entered a material agreementFeb 27, 2026
- Other material eventJan 27, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.